SLC2A1 and Dravet syndrome: The ketogenic diet (KD) is not only considered a valuable non-pharmacological therapeutic option for children with drug-resistant epilepsy (DRE) [1] but it also represents the mainstay of treatment for glucose transporter type 1 deficiency syndrome (GLUT1-DS, OMIM 606777) [2].